BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-34@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: CanSino Biologics Inc. — PCV13i [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Evaluate the Immunogenic
 ity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Hea
 lthy Infants Aged 2 Months (Minimum 6 Weeks).\nSource: https://clinicaltri
 als.gov/study/NCT07017777\nhttps://catalystbrief.girapphe.com/e/34?lang=en
 \nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/34?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
